Title:
DRUG FOR TREATING TUMORS
Document Type and Number:
WIPO Patent Application WO/2023/083362
Kind Code:
A1
Abstract:
Provided is a compound as shown in formula (I), which exhibits an excellent inhibitory activity toward TRK, ALK and ROS1 kinases and mutants thereof, particularly TRK kinases and mutant forms thereof, has a strong inhibitory effect on multiple types of TRK mutated cell (comprising TRK mutated drug-resistant cells), and has superior in vitro and in vivo tumor inhibitory activity relative to an existing control compound. In addition, joint use of the compound and a KRASG12C inhibitor can synergistically enhance the inhibition effect of a drug on tumors having a KRASG12C mutation. The compound has good application prospects as a drug.
Inventors:
FAN LIXUE (CN)
LIU XIBAO (CN)
CHAI XIAOLING (CN)
SHU YUN (CN)
YANG YINPING (CN)
LI BING (CN)
CUI SHUXIANG (CN)
WANG JIE (CN)
ZONG NA (CN)
LIU XIBAO (CN)
CHAI XIAOLING (CN)
SHU YUN (CN)
YANG YINPING (CN)
LI BING (CN)
CUI SHUXIANG (CN)
WANG JIE (CN)
ZONG NA (CN)
Application Number:
PCT/CN2022/131841
Publication Date:
May 19, 2023
Filing Date:
November 15, 2022
Export Citation:
Assignee:
CSPC ZHONGQI PHARMACEUTICAL TECH SHIJIAZHUANG CO LTD (CN)
International Classes:
A61K31/437; A61P35/00; C07D471/04; C07D487/04; C07D519/00
Domestic Patent References:
| WO2021228248A1 | 2021-11-18 | |||
| WO2013088257A1 | 2013-06-20 | |||
| WO2012034095A1 | 2012-03-15 |
Foreign References:
| CN111039946A | 2020-04-21 | |||
| CN108794484A | 2018-11-13 |
Other References:
ZUBERI, M. ET AL.: "Inhibition of RAS: proven and potential vulnerabilities", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 48, no. 5, 1 September 2020 (2020-09-01), XP009546232
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF:
Previous Patent: NEW METHOD FOR IMPROVING QUALITY OF PLATELETS
Next Patent: SYSTEM AND METHOD OF PROCESSING ALUMINUM ALLOY
Next Patent: SYSTEM AND METHOD OF PROCESSING ALUMINUM ALLOY